Short-term Effect of Hypergastrinemia Following Esomeprazole Treatment On Well-Controlled Type 2 Diabetes Mellitus: A Prospective Study.

CONCLUSION: Our study demonstrates that esomeprazole has no extra benefit for the controlled diabetic patient in three months. However, in only metformin-treated subgroup, esomeprazole may prevent the rise in HbA1c level. PMID: 31995024 [PubMed - as supplied by publisher]
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research